Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The underwriters have taken up the over-allotment option in BMS and Celgene-backed oncology drug developer Silverback's initial public offering.

Alexandria Venture Investments was among the participants in the cancer radiotherapy startup's second round in under two months.

Lilly Asia Ventures co-led the first round for the CNS disease drug developer, which is headed by one of its former venture partners.

Stanford University supplied capital to help its AI cell analysis spinout Deepcell close its second funding round.

Science Creates will combine a $20m fund with wet-lab incubation to foster the west of England deep tech ecosystem in partnership with University of Bristol.

Heritage Group has exited Workpath, a developer of in-home care management software, through an acquisition by Ro.

Amgen is a shareholder of Vigil Neuroscience, which is developing microglia-based treatments for neurodegenerative diseases.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Kaiser Foundation Hospitals helped anti-ageing therapy developer BioAge Labs increase its overall funding to $137m.